Targeted delivery of GPX1 or its mimetics to beta cells at the early stages of T1D or pharmacological attempts to boost GPX-1 via the transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) and other beta cell protective candidates may mitigate further destruction of beta cells (Forman and Zhang 2021). This evidence concerns the gene NFE2L2 and type 1 diabetes mellitus.